Technology-based pharma company, Verseon, has submitted a Phase I clinical trial protocol for its lead precision oral anticoagulant (PROAC) — VE-1902 — to the Bellberry Human Research Ethics Committee (HREC) in Australia. Read more


Research from various academic institutions around London has revealed that anticoagulants may increase the risk of stroke in over-65s if they have chronic kidney disease. Read more


Results from a new register-based study have suggested that blood-thinning drugs not only reduce the risk of stroke in patients with atrial fibrillation (AF) but also significantly reduces the risk of dementia in these patients. Read more


Verseon presents further trial data on the low bleeding risk of its family of preclinical anti-coagulant drugs at BioEurope conference Read more